Recovering scientist turned early stage VC A biotech optimist fighting gravity

Confronting Real(i)ty In Cambridge
May 6, 2015

This blog was written by Chuck Wilson, CEO of Unum Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. This is an ongoing saga about finding a new home for my company, Unum Therapeutics. Google tells me that there

7 Comments

Scorecard Of Biobuck M&A Earnouts
April 30, 2015

Milestone payments are an important risk-sharing component in today’s biopharma deal-making toolbox. As it’s a topic I’ve explored in the past (here, here), it’s an opportune time to revisit the stats for how they have performed recently. These contingent value transfers

Leave a comment

It’s The Antigens, Stupid
April 27, 2015

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. “A big asset of VC’s is pattern recognition. It is also often our biggest liability.”  An apt observation tweeted by

Leave a comment

Five Questions To Ask Your Investors Before You Take Their Money
April 22, 2015

This blog was written by Mike Gilman, CEO of Padlock Therapeutics and Atlas EIR, as part of the “From the Trenches” feature of LifeSciVC. Padlock Therapeutics is my second startup, and it’s not nearly as scary as the first one. Not

4 Comments

Data Snapshot: Venture-Backed Biotech Financing Riding High
April 21, 2015

Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well. Last week the quarterly Thomson Reuters data on venture capital funding came out via

Leave a comment

Atlas X: Accelerating Biotech Venture Creation
April 17, 2015

Earlier this week Atlas Venture closed Fund X at $280M, completing our transition to a biotech-only venture firm. After announcing the split of our life science and technology franchises in October 2014 (here), we embarked on the hard work of

Leave a comment

Nucleic Acid Therapeutics Coming of Age
April 1, 2015

This blog was written by Bill Marshall, CEO of miRagen Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The opportunity to use nucleic acids as therapeutic agents is extremely exciting. Creating drugs that affect protein targets that are

Leave a comment

Seed Stage Investing in Talent
March 26, 2015

A few weeks ago, Michael Gladstone wrote a blog, here, about infusing young blood into the ‘C’ suite of biotech. I thought he made a number of important points and great suggestions about the topic. Today, I’d like to expand

2 Comments

Biotech IPO Performance: Discerning Market Or Rising Tide?
March 20, 2015

As anyone following the biotech sector knows, the market for new public offerings has been incredibly strong over the past couple years. And the larger cap stocks in the sector have also outperformed, propelled by product launches and exciting clinical

Leave a comment

Finding Success In Failing Early: All About Execution
March 18, 2015

In a period of surging optimism for our industry, it’s easy to forget that historically most of the therapeutic projects we undertake don’t make it to the market (see the data here if you absolutely have to remind yourself of

1 Comment

Biotech CEOs: Observations In Thermodynamics And Kinetics
March 16, 2015

A great CEO makes all the difference, and a poor one destroys a ton of value. But recruiting great CEOs is often hard, especially when picking, as is most often the case, from a list of potential first-time CEOs. How

4 Comments

Buying Time in 2014: Comparative Holding Periods For VC-Backed M&A Events
March 13, 2015

Over the past decade, in contrast to widely held misperceptions, the Biotech sector has witnessed time-to-IPO metrics very similar to other venture sectors, as I recently blogged on regarding the 2014 IPO Class (here). What wasn’t covered in the prior post was

1 Comment